Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Jan 11;6(1):281-292.
doi: 10.1182/bloodadvances.2021005628.

TCRαβ/CD19 depleted HSCT from an HLA-haploidentical relative to treat children with different nonmalignant disorders

Pietro Merli  1 , Daria Pagliara  1 , Federica Galaverna  1 , Giuseppina Li Pira  1 , Marco Andreani  2 , Giovanna Leone  3 , Donato Amodio  4 , Rita Maria Pinto  1 , Alice Bertaina  1 , Valentina Bertaina  1 , Angela Mastronuzzi  1 , Luisa Strocchio  1 , Emilia Boccieri  1 , Daniela Pende  5 , Michela Falco  6 , Matteo Di Nardo  7 , Francesca Del Bufalo  1 , Mattia Algeri  1 , Franco Locatelli  1   8
Affiliations

TCRαβ/CD19 depleted HSCT from an HLA-haploidentical relative to treat children with different nonmalignant disorders

Pietro Merli et al. Blood Adv. .

Abstract

Several nonmalignant disorders (NMDs), either inherited or acquired, can be cured by allogeneic hematopoietic stem cell transplantation (HSCT). Between January 2012 and April 2020, 70 consecutive children affected by primary immunodeficiencies, inherited/acquired bone marrow failure syndromes, red blood cell disorders, or metabolic diseases, lacking a fully matched donor or requiring urgent transplantation underwent TCRαβ/CD19-depleted haploidentical HSCT from an HLA-partially matched relative as part of a prospective study. The median age at transplant was 3.5 years (range 0.3-16.1); the median time from diagnosis to transplant was 10.5 months (2.7 for SCID patients). Primary engraftment was obtained in 51 patients, while 19 and 2 patients experienced either primary or secondary graft failure (GF), the overall incidence of this complication being 30.4%. Most GFs were observed in children with disease at risk for this complication (eg, aplastic anemia, thalassemia). All but 5 patients experiencing GF were successfully retransplanted. Six patients died of infectious complications (4 had active/recent infections at the time of HSCT), the cumulative incidence of transplant-related mortality (TRM) being 8.5%. Cumulative incidence of grade 1-2 acute GVHD was 14.4% (no patient developed grade 3-4 acute GVHD). Only one patient at risk developed mild chronic GVHD. With a median follow-up of 3.5 years, the 5-year probability of overall and disease-free survival was 91.4% and 86.8%, respectively. In conclusion, TCRαβ/CD19-depleted haploidentical HSCT from an HLA-partially matched relative is confirmed to be an effective treatment of children with NMDs. Prompt donor availability, low incidence of GVHD, and TRM make this strategy an attractive option in NMDs patients. The study is registered at ClinicalTrial.gov as NCT01810120.

PubMed Disclaimer

Figures

None
Graphical abstract
Figure 1.
Figure 1.
Graft failure. (A) Cumulative incidence of GF for the whole cohort. (B) Cumulative incidence of GF for patients affected by diseases at high risk (ie, children affected by HLH, thalassemia, SAA, or osteopetrosis; red line) or at standard risk (blue line) for the complication.
Figure 2.
Figure 2.
Graft-versus-host disease. (A) Cumulative incidence of grade 1-4 acute GVHD. (B) Cumulative incidence of grade 2-4 acute GVHD.
Figure 3.
Figure 3.
Survival. (A) Overall survival (OS) and transplant-related mortality (TRM) of the whole cohort. (B) Event-free survival of the whole cohort. (C) Disease-free survival of the whole cohort (excluding 2 patients with ALD, who had CNS involvement at the time of HSCT). (D) OS according to infectious status at transplant (ie, active or recent infection at the time of HSCT versus no infection).
Figure 4.
Figure 4.
Time-averaged area-under-the-curve (AAUC) AAUC180 for CMV and ADV.
Figure 5.
Figure 5.
Immune reconstitution. (A) Absolute number after haplo-HSCT of CD3+ cells (mean and 95% CI). (B) TCRαβ+ and TCRγδ+ cells (mean and 95% CI). (C) CD4+ and CD8+ T cell subsets (mean and 95% CI). (D) CD20+ B cells (mean and 95% CI).
See this image and copyright information in PMC

References

    1. Kanate AS, Majhail NS, Savani BN, et al. . Indications for hematopoietic cell transplantation and immune effector cell therapy: guidelines from the American Society for Transplantation and Cellular Therapy. Biol Blood Marrow Transplant. 2020;26(7):1247-1256. - PubMed
    1. Lam MT, Coppola S, Krumbach OHF, et al. . A novel disorder involving dyshematopoiesis, inflammation, and HLH due to aberrant CDC42 function. J Exp Med. 2019;216(12):2778-2799. - PMC - PubMed
    1. Thompson AA, Walters MC, Kwiatkowski J, et al. . Gene therapy in patients with transfusion-dependent β-thalassemia. N Engl J Med. 2018; 378(16):1479-1493. - PubMed
    1. Frangoul H, Altshuler D, Cappellini MD, et al. . CRISPR-Cas9 gene editing for sickle cell disease and β-thalassemia. N Engl J Med. 2021;384(3):252-260. - PubMed
    1. Besse K, Maiers M, Confer D, Albrecht M. On modeling human leukocyte antigen-identical sibling match probability for allogeneic hematopoietic cell transplantation: estimating the need for an unrelated donor source. Biol Blood Marrow Transplant. 2016;22(3):410-417. - PubMed

Publication types

Substances

Associated data